{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:37:11Z","timestamp":1785285431519,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofpsychiatricresearch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jpsychires.2017.02.003","type":"journal-article","created":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T07:16:50Z","timestamp":1486192610000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT"],"prefix":"10.1016","volume":"89","author":[{"given":"Masaki","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiteru","family":"Takekita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6736-092X","authenticated-orcid":false,"given":"Yosuke","family":"Koshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Bandou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-3517","authenticated-orcid":false,"given":"Naotaka","family":"Sunada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Onohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Hatashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2017.02.003_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.jpsychires.2017.02.003_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A\u00a0review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.jpsychires.2017.02.003_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/15622975.2013.804195","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders","volume":"14","author":"Bauer","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.02.003_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2009.01.015","article-title":"Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation","volume":"19","author":"Blier","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.02.003_bib5","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1176\/appi.ajp.2009.09020186","article-title":"Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study","volume":"167","author":"Blier","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.02.003_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-3223(01)01262-8","article-title":"A\u00a0double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine","volume":"51","author":"Carpenter","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.02.003_bib7","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jpsychires.2017.02.003_bib8","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1517\/14740338.2015.1085970","article-title":"Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis","volume":"14","author":"Galling","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jpsychires.2017.02.003_bib9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0022-3565(25)12944-3","article-title":"Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain","volume":"277","author":"Haddjeri","year":"1996","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpsychires.2017.02.003_bib10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","article-title":"Development of a rating scale for primary depressive illness","volume":"6","author":"Hamilton","year":"1967","journal-title":"Br. J. Soc. Clin. Psychol."},{"key":"10.1016\/j.jpsychires.2017.02.003_bib11","series-title":"Investigation of Biological and Clinical Predictor of Antidepressant Response for Personalized Medicine in Depression ; a Randomized Controlled Trial: UMIN Clinical Trials Registry","author":"Kato","year":"2011"},{"key":"10.1016\/j.jpsychires.2017.02.003_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/mp.2008.116","article-title":"Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder","volume":"15","author":"Kato","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.02.003_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.02.003_bib14","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e318248581b","article-title":"Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis","volume":"32","author":"Rocha","year":"2012","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2017.02.003_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1176\/appi.ajp.2011.10111645","article-title":"Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study","volume":"168","author":"Rush","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.02.003_bib16","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.02.003_bib17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/sj.tpj.6500477","article-title":"Pharmacogenetic studies in depression: a proposal for methodologic guidelines","volume":"8","author":"Serretti","year":"2008","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.jpsychires.2017.02.003_bib18","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4088\/JCP.v68n0713","article-title":"Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study","volume":"68","author":"Souery","year":"2007","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2017.02.003_bib19","first-page":"CD006528","article-title":"Mirtazapine versus other antidepressive agents for depression","author":"Watanabe","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jpsychires.2017.02.003_bib20","series-title":"The Global Burden of Disease 2004 Update","author":"World Health Organization","year":"2008"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395616308263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395616308263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:01:16Z","timestamp":1749945676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395616308263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":20,"alternative-id":["S0022395616308263"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2017.02.003","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2017.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}